Biogen: phase II study fails in Alzheimer's disease
(CercleFinance.com) - Biogen announced on Wednesday evening that it has stopped the TANGO phase II study evaluating its investigational drug Gosuranemab as a potential treatment for Alzheimer's disease, which failed to meet its primary endpoint.
The company explained that no change was observed at week 78 on the Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB) compared to placebo in patients with mild cognitive impairment due to the disease.
Copyright (c) 2021 CercleFinance.com. All rights reserved.